Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Chronic lymphocytic leukemia
Phase 2 mosunetuzumab CD20×CD3 bispecific antibody T‑cell engager for MRD+ CLL/SLL
This MD Anderson Cancer Center, open-label, single-group Phase 2 study tests whether adding mosunetuzumab—a CD20×CD3 T‑cell–engaging bispecific antibody from Genentech/Roche—can eradicate measurable residual disease…
NCT07566364 Exploratory - New trial Spotlight
Acute myeloid leukemia and MDS
Phase 1 BSB-2002 mutant NPM1–targeted TCR-T cellular therapy in R/R AML
This Phase 1, multicenter, open-label, non-randomized dose-escalation/expansion study tests BSB-2002 for adults with relapsed or refractory acute myeloid leukemia whose leukemia harbors an NPM1 mutation and who are…
NCT07566585 First-in-human - New trial Spotlight
Acute lymphoblastic leukemia
Phase 1 TSLPR-CART anti-TSLPR (CRLF2) CAR T-cell therapy in R/R B-ALL
This first-in-human Phase 1, open-label, 3+3 dose-escalation study sponsored by the National Cancer Institute (NCI) tests autologous TSLPR-CART: a patient’s own T cells engineered to express a chimeric antigen…
NCT07572136 First-in-human - New trial
Other blood cancers and transplant
Phase 1 thiotepa-based conditioning + de-escalated cyclophosphamide (DNA-alkylating immunosuppression) for alloSCT
This Phase 1, open-label transplant-conditioning study tests a thiotepa + busulfan + fludarabine (TBF) backbone before HLA-matched related or unrelated donor peripheral blood stem cell transplantation, paired with a…
NCT07565220 Exploratory - New trial
Other blood cancers and transplant
Phase 1 QUAIL-100 (LGNA-100) attenuated live bacterial γδ T-cell activator post-HSCT
This open-label, first-in-human, single ascending dose study tests QUAIL-100 (also described by Laguna Biotherapeutics as LGNA-100), an attenuated live bacterial immunotherapy intended to harness immune sensing…
NCT07573111 First-in-human - New trial
Other blood cancers and transplant
Pragmatic MRD-guided maintenance after allo-HCT; no single drug target
This prospective, open-label pragmatic study from the Medical College of Wisconsin tests whether using pre-transplant measurable residual disease (MRD) status to *assign* post–allogeneic hematopoietic cell transplant…
NCT07572929 Exploratory - New trial Spotlight
Brain and CNS tumors
Phase 1 8R-70CAR (CD70 CAR-T + CXCR2 “IL-8 receptor” trafficking) in brain metastases
This first-in-human Phase 1, single-center, open-label University of Florida study (IMPACT-MET) tests the safety and feasibility of ex vivo–expanded autologous T cells engineered to express a CD70-directed CAR plus…
NCT07569263 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1/2 ODM-212 pan-TEAD (Hippo/YAP–TEAD) inhibitor combinations in solid tumors
Orion Corporation (Orion Pharma) is running this open-label, multi-cohort Phase 1/2 study to define safety, tolerability, pharmacokinetics/pharmacodynamics, and early efficacy of ODM-212, an oral small-molecule…
NCT07563738 Exploratory - New trial
Multiple solid tumors
Phase 1 NPX372 B7-H7×CD3 T‑cell–engaging bispecific antibody in refractory solid tumors.
NextPoint Therapeutics’ first-in-human, open-label Phase 1 study dose-escalates NPX372, an IgG-like bispecific antibody that binds B7‑H7 (also called HHLA2/B7‑H7 axis target) on tumor cells and CD3 on T cells to…
NCT07563829 First-in-human - Trial result Spotlight
Prostate cancer
Pembrolizumab (PD-1) + Lenvatinib (VEGFR/FGFR multikinase) posts 36% ORR in docetaxel-pretreated mCRPC (KEYNOTE-365)
Pembrolizumab is an anti–PD-1 monoclonal antibody, and lenvatinib is an oral anti-angiogenic multikinase inhibitor (VEGFR/FGFR/PDGFRα/RET/KIT); the combination was tested in KEYNOTE-365 Cohort E (Phase 1b/2) in…
NCT02861573 - Trial result
Prostate cancer
Abiraterone±enzalutamide (AR pathway inhibition) + ADT: early PSA ≤0.2ng/mL flags long-tail OS in STAMPEDE
This post-hoc landmark analysis pooled five randomized Phase 3 STAMPEDE comparisons in metastatic or very high-risk non-metastatic prostate adenocarcinoma (n=7129; recruited Oct 5, 2005–Sept 2, 2016) testing…
- Trial result
Prostate cancer
18F-flotufolastat (rhPSMA-7.3) PSMA-PET lowers bladder activity and lifts detection vs 18F-piflufolastat in low-PSA BCR
18F-piflufolastat (18F-DCFPyL; Pylarify) and 18F-flotufolastat (18F-rhPSMA-7.3; Posluma) are PSMA-targeted PET radiotracers for localizing recurrent prostate cancer; this prospective, multicentre, intra-patient…
NCT06604442 - Trial result Spotlight
Non-small cell lung cancer
THIO (telomere-targeting nucleoside analog) → sequential cemiplimab (PD-1) posts 16.9-mo OS signal in 3L ICI-resistant NSCLC
THIO is a first-in-class telomere-targeting agent designed to disrupt telomere integrity in telomerase-positive tumor cells and was sequenced before cemiplimab (a PD-1 antibody) in the multicenter, open-label Phase 2…
NCT05208944 - Trial result
Non-small cell lung cancer
ctFE (tumor-naïve ctDNA burden metric) predicts OS/PFS early during chemoRT for LA/oligometastatic NSCLC
In the prospective Phase II NCT03916419 trial, circulating tumor fraction estimate (ctFE)—a machine learning-derived composite of ctDNA burden from a clinically available, tumor-naïve assay—was measured at baseline…
NCT03916419 - Trial result
Non-small cell lung cancer
Amivantamab (EGFR/MET bispecific) + Lazertinib (EGFR TKI) Suppresses MET/EGFR Resistance vs Osimertinib, Extends 2L PFS
Amivantamab is an IV bispecific antibody targeting EGFR and MET, combined here with lazertinib, a 3rd-gen EGFR tyrosine kinase inhibitor; this MARIPOSA (Phase 3; NCT04487080) brief report used paired baseline/EOT…
NCT04487080 - Trial result
Non-small cell lung cancer
Tiragolumab (anti‑TIGIT) + atezolizumab (PD‑L1) + chemo misses PFS/OS vs pembrolizumab‑chemo in 1L nonsquamous NSCLC
SKYSCRAPER‑06 (Phase 3; NCT04619797) randomized previously untreated, locally advanced unresectable/metastatic nonsquamous NSCLC without EGFR/ALK alterations to tiragolumab (anti‑TIGIT) + atezolizumab (anti‑PD‑L1) +…
NCT04619797 - Trial result
Kidney cancer
Pembrolizumab (PD-1) + radiotherapy MDT trends toward longer PFS in oligometastatic ccRCC
Radiotherapy-based metastasis-directed therapy (MDT) with or without pembrolizumab maintenance was compared in a pooled, exploratory analysis of two prospective single-arm Phase 2 trials (MDT+ICI: NCT02855203; MDT…
NCT02855203 - Trial result Spotlight
Lymphoma
Pirtobrutinib (non-covalent BTK inhibitor) drives 82.5% ORR in R/R Waldenström’s at ~3-year follow-up
Pirtobrutinib is a highly selective, non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor evaluated as monotherapy in the open-label, multicentre Phase 1/2 BRUIN trial (NCT03740529) in relapsed/refractory…
NCT03740529 - Trial result
Colorectal cancer
FOLFOXIRI (triplet chemo) + capecitabine-RT delivers 20.5% pCR in high-risk LARC
Modified FOLFOXIRI (5-FU/leucovorin, oxaliplatin, irinotecan) induction chemotherapy was tested as part of a Phase II, multicenter, single-arm total neoadjuvant approach in Chinese patients with high-risk,…
NCT01941641 - Trial result
Myeloproliferative neoplasms
Bomedemstat (LSD1 inhibitor) shrinks spleen and improves fibrosis markers in JAKi-refractory myelofibrosis
Bomedemstat (IMG-7289/MK-3543) is an oral, irreversible lysine-specific demethylase 1 (LSD1/KDM1A) inhibitor evaluated in an open-label Phase 1/2 study in myelofibrosis patients refractory/resistant to, inadequately…
NCT03136185 - Trial result Spotlight
Pancreatic cancer
Intraperitoneal nivolumab (PD-1 blockade) yields 78% ascites control with minimal toxicity in GI/pancreaticobiliary cancers
Nivolumab (Opdivo), an anti–PD-1 immune checkpoint inhibitor, was administered intraperitoneally (IP) at 20 mg in 100 mL saline after paracentesis in a small, single-arm study of cytology-confirmed malignant ascites…
NCT05745233 - New trial
Breast cancer
Phase 1b TRICK-NK TROP2-targeted CAR-NK (IL-15 armored, TGFBR2 knockout) + T-DXd
This Phase 1b, open-label dose-escalation then dose-expansion study at MD Anderson tests an allogeneic cord blood–derived NK-cell product engineered with a TROP2-directed CAR plus IL-15 expression (to enhance NK…
NCT07553390 Exploratory - New trial
Breast cancer
Phase 1b/2 PIKTOR (serabelisib PI3Kα inhibitor + sapanisertib dual mTORC1/2 inhibitor)
This Phase 1b/2, multi-center, open-label umbrella study sponsored by Faeth Therapeutics tests “PIKTOR,” an all-oral combination of serabelisib (a PI3K-alpha inhibitor; also referenced as INK-1117 in some materials)…
NCT07558733 Exploratory - New trial
Breast cancer
Phase 2 MO-03 live biotherapeutic (microbiome modulator) plus pembrolizumab PD-1 blockade in early TNBC
This single-group, open-label Phase 2 study tests whether adding MO-03—a live biotherapeutic product intended to modulate the gut microbiome—can improve outcomes when layered onto standard neoadjuvant pembrolizumab…
NCT07552181 Exploratory - New trial Spotlight
Brain and CNS tumors
Phase 1 FT536 MICA/B-directed CAR-NK (MICA/MICB-targeted) for recurrent grade 4 astrocytoma
This single-center, first-in–cancer-type Phase 1, open-label, sequential dose-escalation study tests intratumoral FT536 in adults with recurrent WHO grade 4 astrocytoma (eligible regardless of IDH mutation status)…
NCT07560865 First-in-human - New trial
Brain and CNS tumors
Phase 1 RNA-LP vaccine: CMV pp65–LAMP mRNA + autologous tumor mRNA immunotherapy
This first-in-human Phase 1, open-label, dose-escalation study at the University of Florida tests the manufacturing feasibility, safety, and maximum tolerated dose of an intravenous RNA–lipid particle (RNA-LP) cancer…
NCT07492316 First-in-human - New trial Spotlight
Pancreatic cancer
Phase 3 atebimetinib MEK1/2 inhibitor plus modified GnP vs standard GnP in metastatic PDAC
Immuneering’s MAPKeeper 301 is a randomized, open-label Phase 3 trial testing whether adding atebimetinib—an oral small-molecule MEK1/MEK2 inhibitor targeting the MAPK pathway—to a modified schedule of gemcitabine +…
NCT07562152 Registrational - New trial
Lymphoma
Phase 2 nivolumab PD-1 checkpoint inhibitor plus AVD chemo in early-stage pediatric cHL
This MD Anderson–sponsored Phase 2, open-label, single-arm study evaluates nivolumab (Bristol Myers Squibb; PD-1/CD279–blocking monoclonal antibody that reinvigorates anti-tumor T cells) combined with AVD…
NCT07551583 Exploratory - New trial
Small cell lung cancer
Phase 2 FHD-286 SMARCA4/2 (BRG1/BRM) ATPase inhibitor in POU2F3+ SCLC
This single-arm Phase 2 study tests FHD-286, an oral small-molecule dual SMARCA4/SMARCA2 (BRG1/BRM) ATPase inhibitor that targets the SWI/SNF (BAF) chromatin remodeling complex, in people with POU2F3-expressing small…
NCT07551635 Exploratory - New trial
Sarcoma and GIST
Phase 2 methotrexate dihydrofolate reductase inhibitor optimizes HD‑MTX discharge in osteosarcoma.
This Phase 2, multicenter supportive-care/operations study from Wake Forest University Health Sciences (Wake Forest Baptist) tests whether patients with newly diagnosed high‑grade osteosarcoma (children, adolescents,…
NCT07560826 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.